目的:检测miR-34c-3p与增殖细胞核抗原(PCNA)在三阴性乳腺癌(TNBC)组织和血清中的表达,分析二者的相关性,探讨其在TNBC发病中的意义。方法:选择2017年12月至2019年12月于空军军医大学第一附属医院就诊的72例TNBC患者作为实验组(A组),以...目的:检测miR-34c-3p与增殖细胞核抗原(PCNA)在三阴性乳腺癌(TNBC)组织和血清中的表达,分析二者的相关性,探讨其在TNBC发病中的意义。方法:选择2017年12月至2019年12月于空军军医大学第一附属医院就诊的72例TNBC患者作为实验组(A组),以同期就诊的60例乳腺纤维腺瘤或乳腺腺病患者为对照组(B组)。采用Real-time RT-PCR检测乳腺组织标本中miR-34c-3p m RNA及PCNA m RNA的表达;免疫组化检测两组乳腺组织中PCNA蛋白表达;ELISA法检测血清中PCNA的表达。并进一步分析癌组织中miR-34c-3p m RNA的表达与癌组织中PCNA m RNA及血清PCNA水平的相关性。结果:A、B组miR-34c-3p m RNA的相对表达量分别为0.884±0.159及1.255±0.131,A组明显低于B组,差异有统计学意义(P<0.001)。A、B组PCNA m RNA的相对表达量分别为1.544±0.215及1.230±0.204,A组表达高于B组,差异有统计学意义(P<0.001)。免疫组化检测PCNA蛋白表达,A组阳性例数为50例,阴性例数为22例;B组阳性例数为21例,阴性例数为39例;A组阳性率明显高于B组,差异有统计学意义(P<0.001)。两组患者血清中PCNA的表达,A组[(383.194±110.832)pg/ml]明显高于B组[(257.867±101.697)pg/ml],差异有统计学意义(P<0.001)。将A组TNBC患者肿瘤组织miR-34c-3p m RNA表达结果分别与PCNA m RNA表达结果及其血清中PCNA表达结果进行Pearson相关分析,结果显示:miR-34c-3p m RNA与PCNA m RNA及血清PCNA均呈明显负相关关系(P<0.001、P=0.024<0.05)。结论:TNBC组织中miR-34c-3p表达下调,PCNA在癌组织及血清中均表达上调,二者在TNBC患者组织和血清中呈明显负相关关系。miR-34c-3p与PCNA可能在TNBC的发病中起着重要的作用。展开更多
Through molecular dynamics（MD） simulation, the dependencies of temperature, grain size and strain rate on the mechanical properties were studied. The simulation results demonstrated that the strain rate from 0.05 to...Through molecular dynamics（MD） simulation, the dependencies of temperature, grain size and strain rate on the mechanical properties were studied. The simulation results demonstrated that the strain rate from 0.05 to 2 ns–1 affected the Young＇s modulus of nickel nanowires slightly, whereas the yield stress increased. The Young＇s modulus decreased approximately linearly; however, the yield stress firstly increased and subsequently dropped as the temperature increased. The Young＇s modulus and yield stress increased as the mean grain size increased from 2.66 to 6.72 nm. Moreover, certain efforts have been made in the microstructure evolution with mechanical properties association under uniaxial tension. Certain phenomena such as the formation of twin structures, which were found in nanowires with larger grain size at higher strain rate and lower temperature, as well as the movement of grain boundaries and dislocation, were detected and discussed in detail. The results demonstrated that the plastic deformation was mainly accommodated by the motion of grain boundaries for smaller grain size. However, for larger grain size, the formations of stacking faults and twins were the main mechanisms of plastic deformation in the polycrystalline nickel nanowire.展开更多
目的对人表皮生长因子受体2(HER-2)低表达乳腺癌的临床特征、抗体偶联药物(antibody drug conjugates,ADCs)在HER-2低表达人群的治疗进展进行总结。方法以“HER-2 low breast cancer、antibody drug conjugates”为英文关键词在PubMed...目的对人表皮生长因子受体2(HER-2)低表达乳腺癌的临床特征、抗体偶联药物(antibody drug conjugates,ADCs)在HER-2低表达人群的治疗进展进行总结。方法以“HER-2 low breast cancer、antibody drug conjugates”为英文关键词在PubMed数据库进行检索,检索时间为自建库至2022年12月。纳入标准:(1)HER-2低表达乳腺癌的生物学和临床特征;(2)ADCs药物的临床前试验和临床试验。排除标准:(1)个案报道;(2)重复的临床试验。最终纳入50篇文献。结果随着ADCs药物临床数据的不断公布,HER-2低表达乳腺癌的概念逐渐被重视。HER-2低表达乳腺癌有望成为一个全新的治疗亚型。以T-Dxd为代表的ADCs药物,包括Trastuzumab-emtansine、Trastuzumab-deruxtecan、Trastuzumab-Duocarmazine、ARX-788、XMT-1522、MEDI4276、A166和MRG002已经在HER-2低表达乳腺癌人群中展示出较好的疗效,相信新型ADCs在不久的未来能够成为HER-2低表达乳腺癌人群的治疗新选择。结论以T-Dxd为代表的新型ADCs的不断问世将成为HER-2低表达乳腺癌人群的治疗新选择,并改善该人群的预后。展开更多
文摘目的:检测miR-34c-3p与增殖细胞核抗原(PCNA)在三阴性乳腺癌(TNBC)组织和血清中的表达,分析二者的相关性,探讨其在TNBC发病中的意义。方法:选择2017年12月至2019年12月于空军军医大学第一附属医院就诊的72例TNBC患者作为实验组(A组),以同期就诊的60例乳腺纤维腺瘤或乳腺腺病患者为对照组(B组)。采用Real-time RT-PCR检测乳腺组织标本中miR-34c-3p m RNA及PCNA m RNA的表达;免疫组化检测两组乳腺组织中PCNA蛋白表达;ELISA法检测血清中PCNA的表达。并进一步分析癌组织中miR-34c-3p m RNA的表达与癌组织中PCNA m RNA及血清PCNA水平的相关性。结果:A、B组miR-34c-3p m RNA的相对表达量分别为0.884±0.159及1.255±0.131,A组明显低于B组,差异有统计学意义(P<0.001)。A、B组PCNA m RNA的相对表达量分别为1.544±0.215及1.230±0.204,A组表达高于B组,差异有统计学意义(P<0.001)。免疫组化检测PCNA蛋白表达,A组阳性例数为50例,阴性例数为22例;B组阳性例数为21例,阴性例数为39例;A组阳性率明显高于B组,差异有统计学意义(P<0.001)。两组患者血清中PCNA的表达,A组[(383.194±110.832)pg/ml]明显高于B组[(257.867±101.697)pg/ml],差异有统计学意义(P<0.001)。将A组TNBC患者肿瘤组织miR-34c-3p m RNA表达结果分别与PCNA m RNA表达结果及其血清中PCNA表达结果进行Pearson相关分析,结果显示:miR-34c-3p m RNA与PCNA m RNA及血清PCNA均呈明显负相关关系(P<0.001、P=0.024<0.05)。结论:TNBC组织中miR-34c-3p表达下调,PCNA在癌组织及血清中均表达上调,二者在TNBC患者组织和血清中呈明显负相关关系。miR-34c-3p与PCNA可能在TNBC的发病中起着重要的作用。
基金Supported by the National Natural Science Foundation of China(11102139,11472195)the Natural Science Foundation of Hubei Province of China(2014CFB713)
文摘Through molecular dynamics（MD） simulation, the dependencies of temperature, grain size and strain rate on the mechanical properties were studied. The simulation results demonstrated that the strain rate from 0.05 to 2 ns–1 affected the Young＇s modulus of nickel nanowires slightly, whereas the yield stress increased. The Young＇s modulus decreased approximately linearly; however, the yield stress firstly increased and subsequently dropped as the temperature increased. The Young＇s modulus and yield stress increased as the mean grain size increased from 2.66 to 6.72 nm. Moreover, certain efforts have been made in the microstructure evolution with mechanical properties association under uniaxial tension. Certain phenomena such as the formation of twin structures, which were found in nanowires with larger grain size at higher strain rate and lower temperature, as well as the movement of grain boundaries and dislocation, were detected and discussed in detail. The results demonstrated that the plastic deformation was mainly accommodated by the motion of grain boundaries for smaller grain size. However, for larger grain size, the formations of stacking faults and twins were the main mechanisms of plastic deformation in the polycrystalline nickel nanowire.
文摘目的对人表皮生长因子受体2(HER-2)低表达乳腺癌的临床特征、抗体偶联药物(antibody drug conjugates,ADCs)在HER-2低表达人群的治疗进展进行总结。方法以“HER-2 low breast cancer、antibody drug conjugates”为英文关键词在PubMed数据库进行检索,检索时间为自建库至2022年12月。纳入标准:(1)HER-2低表达乳腺癌的生物学和临床特征;(2)ADCs药物的临床前试验和临床试验。排除标准:(1)个案报道;(2)重复的临床试验。最终纳入50篇文献。结果随着ADCs药物临床数据的不断公布,HER-2低表达乳腺癌的概念逐渐被重视。HER-2低表达乳腺癌有望成为一个全新的治疗亚型。以T-Dxd为代表的ADCs药物,包括Trastuzumab-emtansine、Trastuzumab-deruxtecan、Trastuzumab-Duocarmazine、ARX-788、XMT-1522、MEDI4276、A166和MRG002已经在HER-2低表达乳腺癌人群中展示出较好的疗效,相信新型ADCs在不久的未来能够成为HER-2低表达乳腺癌人群的治疗新选择。结论以T-Dxd为代表的新型ADCs的不断问世将成为HER-2低表达乳腺癌人群的治疗新选择,并改善该人群的预后。
